Authors:
VERGIN H
MAHR G
METZ R
EICHINGER A
NITSCHE V
Citation: H. Vergin et al., INVESTIGATION ON THE BIOEQUIVALENCE OF 2 ORAL PREPARATIONS CONTAININGSPIRONOLACTONE AND FUROSEMIDE, International journal of clinical pharmacology and therapeutics, 36(4), 1998, pp. 231-238
Authors:
STOHRER M
EICHINGER A
SCHLACHTER M
STANGASSINGER M
Citation: M. Stohrer et al., PROTECTIVE EFFECT OF VITAMIN-E IN A RAT MODEL OF FOCAL CEREBRAL-ISCHEMIA, Zeitschrift fur Naturforschung. C, A journal of biosciences, 53(3-4), 1998, pp. 273-278
Authors:
VERGIN H
MAHR G
METZ R
EICHINGER A
NITSCHE V
MARTENS H
Citation: H. Vergin et al., ANALYSIS OF METABOLITES - A NEW APPROACH TO BIOEQUIVALENCE STUDIES OFSPIRONOLACTONE FORMULATIONS, International journal of clinical pharmacology and therapeutics, 35(8), 1997, pp. 334-340
Citation: H. Schutz et al., RELATIVE BIOAVAILABILITY OF 3 DIFFERENT CHLORMEZANONE 200-MG PREPARATIONS AFTER SINGLE-DOSE ORAL-ADMINISTRATION, International journal of clinical pharmacology and therapeutics, 35(3), 1997, pp. 112-116
Authors:
BOHNER H
JANIAK PS
NITSCHE V
EICHINGER A
SCHUTZ H
Citation: H. Bohner et al., RELATIVE BIOAVAILABILITY OF DIFFERENT BUTAMIRATE CITRATE PREPARATIONSAFTER SINGLE-DOSE ORAL-ADMINISTRATION TO 18 HEALTHY-VOLUNTEERS, International journal of clinical pharmacology and therapeutics, 35(3), 1997, pp. 117-122
Authors:
ENGH RA
BRANDSTETTER H
SUCHER G
EICHINGER A
BAUMANN U
BODE W
HUBER R
POLL T
RUDOLPH R
VONDERSAAL W
Citation: Ra. Engh et al., ENZYME FLEXIBILITY, SOLVENT AND WEAK-INTERACTIONS CHARACTERIZE THROMBIN-LIGAND INTERACTIONS - IMPLICATIONS FOR DRUG DESIGN, Structure, 4(11), 1996, pp. 1353-1362
Authors:
VONDERSAAL W
ENGH RA
EICHINGER A
GABRIEL B
KUCZNIERZ R
SAUER J
Citation: W. Vondersaal et al., SYNTHESES AND SELECTIVE INHIBITORY ACTIVITIES OF TERPHENYL-BISAMIDINES FOR SERINE PROTEASES, Archiv der pharmazie, 329(2), 1996, pp. 73-82
Citation: A. Eichinger et al., COMPUTER-AIDED DECISION SYSTEM FOR FUTURE STRATEGIES IN OLD HYDROPOWER PLANTS, Cybernetics and systems, 25(1), 1994, pp. 73-80